Literature DB >> 16885349

SPARC represses E-cadherin and induces mesenchymal transition during melanoma development.

Guillaume Robert1, Cédric Gaggioli, Olivier Bailet, Carine Chavey, Patricia Abbe, Edith Aberdam, Emilie Sabatié, Amparo Cano, Antonio Garcia de Herreros, Robert Ballotti, Sophie Tartare-Deckert.   

Abstract

During progression of melanoma, loss of the cell-cell adhesion molecule E-cadherin contributes to uncontrolled growth and invasive behavior of transformed melanocytes. Secreted protein acidic and rich in cysteine (SPARC) is a nonstructural matricellular protein that regulates cell-matrix interactions leading to alterations in cell adhesion and proliferation. Overexpression of SPARC has been associated with progression of various cancers, including melanoma; however, its role in primary tumor development is not well defined. We show that normal human melanocytes overexpressing SPARC adopt a fibroblast-like morphology, concomitant with loss of E-cadherin and P-cadherin expression, and increased expression of mesenchymal markers. Concurrent with these changes, SPARC expression stimulates melanocyte motility and melanoma cell invasion. Expression of SPARC results in transcriptional down-regulation of E-cadherin that correlates with induction of Snail, a repressor of E-cadherin. Conversely, SPARC depletion leads to up-regulation of E-cadherin and reduces Snail levels, and SPARC-null cells exhibit a marked change in their mesenchymal phenotype. Finally, analysis of SPARC, Snail, and E-cadherin levels in melanocytes and malignant melanoma cell lines further supports the functional relationship among these proteins during melanoma progression. Our findings provide evidence for the role of SPARC in early transformation of melanocytes and identify a novel mechanism, whereby tumor-derived SPARC promotes tumorigenesis by mediating Snail induction and E-cadherin suppression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885349     DOI: 10.1158/0008-5472.CAN-05-3189

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

Review 1.  Snail family regulation and epithelial mesenchymal transitions in breast cancer progression.

Authors:  Antonio Garcia de Herreros; Sandra Peiró; Mayssaa Nassour; Pierre Savagner
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-09       Impact factor: 2.673

2.  Development of Secreted Protein and Acidic and Rich in Cysteine (SPARC) Targeted Nanoparticles for the Prognostic Molecular Imaging of Metastatic Prostate Cancer.

Authors:  Stephanie Thomas; Peter Waterman; Suelin Chen; Brett Marinelli; Marc Seaman; Scott Rodig; Robert W Ross; Lee Josephson; Ralph Weissleder; Kimberly A Kelly
Journal:  J Nanomed Nanotechnol       Date:  2011-08

3.  Scattering of Cell Clusters in Confinement.

Authors:  Amit Pathak
Journal:  Biophys J       Date:  2016-10-04       Impact factor: 4.033

Review 4.  The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease.

Authors:  Sharon L I Wong; Maria B Sukkar
Journal:  Br J Pharmacol       Date:  2016-11-25       Impact factor: 8.739

5.  Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.

Authors:  Olivier Bailet; Nina Fenouille; Patricia Abbe; Guillaume Robert; Stéphane Rocchi; Nadège Gonthier; Christophe Denoyelle; Michel Ticchioni; Jean-Paul Ortonne; Robert Ballotti; Marcel Deckert; Sophie Tartare-Deckert
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

6.  SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling.

Authors:  Jing Nie; E Helene Sage
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

7.  Differential Expression of SPARC in Intestinal-type Gastric Cancer Correlates with Tumor Progression and Nodal Spread.

Authors:  Konrad Franke; Stacy Carl-McGrath; Friedrich-Wilhelm Röhl; Uwe Lendeckel; Matthias Pa Ebert; Marc Tänzer; Matthias Pross; Christoph Röcken
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

8.  Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

Authors:  Alexandre Chlenski; Lisa J Guerrero; Radhika Peddinti; Jared A Spitz; Payton T Leonhardt; Qiwei Yang; Yufeng Tian; Helen R Salwen; Susan L Cohn
Journal:  Mol Cancer       Date:  2010-06-04       Impact factor: 27.401

9.  SPARC functions as an inhibitor of adipogenesis.

Authors:  Jing Nie; E Helene Sage
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

10.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.